Vanguard Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,713,520 shares of CPRX stock, worth $202 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,713,520
Previous 8,765,835
0.6%
Holding current value
$202 Million
Previous $190 Million
9.76%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CPRX
# of Institutions
393Shares Held
106MCall Options Held
164KPut Options Held
439K-
Black Rock Inc. New York, NY18.7MShares$433 Million0.01% of portfolio
-
State Street Corp Boston, MA6.41MShares$148 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.97MShares$115 Million1.82% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.54MShares$82.2 Million0.1% of portfolio
-
Terry Smith Fundsmith LLP | London, X03.36MShares$78 Million0.34% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.38B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...